Liberty Health Sciences Inc. Signs Exclusive Licensing and Raw Materials Agreement With Mary's Medicinals to Provide Floridians With Range of Award-Winning Cannabis Products

TORONTO, Oct. 24, 2017 /CNW/ - Liberty Health Sciences Inc. (CSE:LHS) (OTCBB:LHSIF) ("Liberty" or the "Company") today announced a partnership with Colorado-based MM Technology Holdings, LLC ("Mary's") to bring its award-winning line of Mary's Medicinals® cannabis products to the Florida market. Under the three-year agreement, Liberty will produce and distribute a suite of effective and reliable products from Mary's under license in the State of Florida to further optimize patient care. The agreement is subject to approval by the Florida Department of Health, Office of Medical Marijuana Use as is required under Florida law.

"Our goal is to provide the best available medical cannabis products to our patients and Mary's has a proven track record of success in the space," said George Scorsis, CEO and Director of Liberty. "We're very pleased to be partnering with the company to bring their award-winning products to the Florida market and offer alternative methods of using medical cannabis. This partnership further ensures our patients have access to the most effective medicine on the market today."

Liberty is committed to delivering high-quality, clean and safe pharmaceutical grade cannabis and this agreement with Mary's elevates the number of cutting-edge products available to its patients. Best known as the developer and exclusive distributor of the award-winning Transdermal Cannabis Patch, Mary innovates at the intersection of technology and horticulture and is transforming how people view and utilize cannabis, developing products that maximize the benefits of cannabinoids, terpenes and other plant nutrients. The agreement with Mary's allows Liberty to license and produce the following products:

• Mary's Medicinals® Transdermal patches
• Mary's Medicinals® Transdermal gels
• Mary's Medicinals® Transdermal/topical compounds
• Mary's Medicinals® Capsules
• Mary's Medicinals® Tinctures
• Mary's Medicinals® Muscle Freeze
• Mary's Medicinals® Vape Pens
• Mary's Medicinals® Distillates

Mary's creates effective and natural pain-relief products, utilizing clinically tested, clean and accurate delivery methods. Most importantly, the company is dedicated to developing innovative products, which have garnered numerous accolades including 2014 Invention of the Year in the Cannabis Business Awards, Most Innovative Product at the CannAwards and Best New Product at the High Times Cannabis Cup.

"Mary's and Liberty share a patient-first mentality, which makes our partnership a natural fit," said Lynn Honderd, CEO of Mary's. "We're pleased to join forces with the team at Liberty to help bring new forms of relief to Florida patients."

For more information on Liberty, please visit www.libertyhealthsciences.com

About Liberty Health Sciences Inc.
Liberty Health Sciences Inc. ("Liberty") is an investor and operator in the medical cannabis market, capitalizing on new and existing opportunities in U.S. states where medical cannabis is legal. Liberty's stringent investment criteria for expansion maximizes returns to shareholders, while focusing on significant near and mid-term opportunities.  Liberty has an extensive background in highly regulated industries, with expertise in becoming a low-cost producer.  Liberty leverages commercial greenhouse knowledge to deliver high-quality, clean and safe pharmaceutical grade cannabis to patients. 

About Mary's Medicinals
Best known as the developer and exclusive distributor of the award-winning transdermal cannabis patch, Mary's Medicinals is a wellness company innovating at the intersection of engineering, technology and horticulture. Mary's mission is to transform how people view and utilize cannabis by developing products that isolate the benefits of cannabinoids and other vital plant extracts for optimum patient care. All Mary's Medicinals products have the Seal of Approval from The Realm of Caring. For more information, please visit www.marysmedicinals.com.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: Certain information in this news release constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as "may", "should", "anticipate", "expect", "believe", "plan", "intend", "subject to" or the negative of these terms and similar expressions. Forward-looking statements in this news release include, but are not limited to, expectations concerning receipt of approval from the Florida Department of Health, Office of Medical Marijuana Use. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; future legislative and regulatory developments involving medical marijuana; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the medical marijuana industry in the United States generally, income tax and regulatory matters; the ability of Liberty to implement its business strategies; competition; crop failure; currency and interest rate fluctuations and other risks.

Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

SOURCE Liberty Health Sciences Inc.

For U.S. media inquiries, please contact: Ober Delgado, Edelman, [email protected], 305.358.2830; For Canadian media inquiries, please contact: Matt Salvatore, Edelman,[email protected], 613.315.7362